Reach Us +443308085114
Risk Assessment: A Pragmatic Approach To Develop Biosimilars | 10448
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Risk assessment: A pragmatic approach to develop biosimilars

2nd International Conference and Exhibition on Biowaivers & Biosimilars

Harish Shandilya

Accepted Abstracts: J Bioanal Biomed

DOI: 10.4172/1948-593X.S1.011

Therapeutic proteins and antibodies are one of the most important and rapidly growing segments of the pharmaceutical industry. By 2016, yearly spending on brand biologics will reach $60 billion. But affordability of these life saving drugs is a challenge specifically in the developing world. There is a pragmatic solution on the horizon for safe, affordable, biosimilar versions of these critical therapies. Biosimilars have been proved safe and effective in Europe for last seven years but in USA the guidelines from US FDA to develop biosimilars is still awaited. As we know the genesis of biosimilars is providing cheap, affordable drugs for the masses, specifically in emerging markets where affordability of critical drugs is a major concern. This presentation will focus on how to design the development in a cost effective way keeping a close watch on Critical Quality Attributes (CQAs) of the drug. What and how much is required to establish the biosimilarity of the drug is more important. There is at least a 100 fold improvement in assays available during the development of innovator molecules and assays available now. It is now possible to accurately quantitate the chemical status of each residue in a protein molecule and measure minute structural variance using various orthogonal approaches. In addition, the relevance and extent of clinic trails for innovators and for biosimilars will be discussed too.
Harish Shandilya is heading Biocharacterization of therapeutic proteins at INTAS Biopharmaceuticals Ltd. Ahmedabad, India. He is working with INTAS for last 6 years now. Prior to this assignment he has developed clones for many biotherapeutic proteins. He is a molecular biologist by training and has worked at various prestigious institutions in India and abroad. He did his post doctoral work at Vanderbilt University Medical Center, Nashville, USA. Before joining Intas, he was associated with University of Pittsburgh, USA. He has done his Ph.D. degree (1999) from M.D. University, Rohtak, India in collaboration with ICMR, India. He has published more than 20 research papers in reputed journals. He has experience of coordinating multiple biosimilar product development programs for domestic and regulated market projects.